27.05.2026 • News

Wacker completes sale of shares in Siltronic

Wacker has sold 2.1 million Siltronic shares for € 89.35 per Siltronic share. The sale corresponds to 7% of Siltronic's share capital and reduces Wacker's stake in Siltronic to around 24%.

Photo
Wacker CEO Christian Hartel
© Wacker

The gross proceeds from the placement amounted to around EUR 188 million. The shares were sold in a private placement by way of an accelerated bookbuilding process exclusively to qualified investors and international institutional investors.

"We are very pleased with the development of Siltronic and continue to support the company's strategy," says CEO Christian Hartel. "The proceeds from the transaction will strengthen our financial position and create additional scope to invest in future growth. At the same time, Wacker remains Siltronic's largest shareholder," Hartel continues.

Company

Logo:

Wacker Chemie

Hanns-Seidel-Platz 4
81737 Munich
Germany

Company contact







Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

most read